These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28689663)

  • 1. New hepatitis C antiviral treatments eliminate the virus.
    Doyle JS; Thompson AJ; Higgs P; Stoove M; Dietze PM; Hellard ME
    Lancet; 2017 Jul; 390(10092):358-359. PubMed ID: 28689663
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.
    Ohashi H; Koizumi Y; Fukano K; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Jun; 114(23):E4527-E4529. PubMed ID: 28512226
    [No Abstract]   [Full Text] [Related]  

  • 3. New Direct-Acting Antiviral Agents Can Be Hepatotoxic in Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis.
    Ou P; Li F; Chen J
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1669-1671. PubMed ID: 27329403
    [No Abstract]   [Full Text] [Related]  

  • 4. In Reference to: Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
    Pesano RL
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1224. PubMed ID: 26972984
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct-acting antiviral therapy for hepatitis E virus?
    Kamar N; Wang W; Dalton HR; Pan Q
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):154-155. PubMed ID: 28404127
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.
    Thibault V
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):145-147. PubMed ID: 29371018
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical development of hepatitis C virus host-targeting agents.
    Zeisel MB; Baumert TF
    Lancet; 2017 Feb; 389(10070):674-675. PubMed ID: 28087068
    [No Abstract]   [Full Text] [Related]  

  • 8. The iron homeostasis network and hepatitis C virus - a new challenge in the era of directly acting antivirals.
    Sikorska K
    Virulence; 2016 Aug; 7(6):620-2. PubMed ID: 27196953
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy.
    Artemova M; Abdurakhmanov D; Ignatova T; Mukhin N
    Hepatology; 2017 May; 65(5):1770-1771. PubMed ID: 27943361
    [No Abstract]   [Full Text] [Related]  

  • 10. Timing Is Everything: Managing Hepatitis C Virus in Liver Transplant Candidates.
    Aronsohn A
    Transplantation; 2017 May; 101(5):898-899. PubMed ID: 28252562
    [No Abstract]   [Full Text] [Related]  

  • 11. Direct-acting antiviral treatment for hepatitis C.
    Holmes JA; Rutledge SM; Chung RT
    Lancet; 2019 Apr; 393(10179):1392-1394. PubMed ID: 30765125
    [No Abstract]   [Full Text] [Related]  

  • 12. How to eliminate HCV infection by antiviral treatment.
    Martin NK; Vickerman P; Hickman M
    J Hepatol; 2017 Jul; 67(1):5-6. PubMed ID: 28323120
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current management of hepatitis C].
    Lange CM
    Med Monatsschr Pharm; 2015 Sep; 38(9):337-44; quiz 345-6. PubMed ID: 26731851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance.
    Beste LA
    JAMA Netw Open; 2019 Jun; 2(6):e194757. PubMed ID: 31173111
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical timing and benefit of antiviral treatment for hepatitis C].
    Chen LC; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal timing for hepatitis C antiviral therapy in the peritransplant period?
    Cholankeril G; Wong RJ; Kim D; Ahmed A
    Hepatology; 2017 Sep; 66(3):1004. PubMed ID: 28586088
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.
    Maan R; Feld JJ; Duarte-Rojo A
    Aliment Pharmacol Ther; 2017 Aug; 46(3):379-380. PubMed ID: 28677289
    [No Abstract]   [Full Text] [Related]  

  • 18. ANA, lupus and hepatitis C. Comment to "infection with hepatitis C virus, interferon α and lupus: an odd association".
    Martín-Gómez MA
    Nefrologia; 2015; 35(5):506-7. PubMed ID: 26388351
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. We can cure hepatitis C virus after transplant, but what is the best regimen?
    Verna EC
    Liver Transpl; 2016 Nov; 22(11):1463-1465. PubMed ID: 27650171
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.